KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Operating Income (2016 - 2025)

Historic Operating Income for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $1.2 billion.

  • Vertex Pharmaceuticals' Operating Income rose 1753.41% to $1.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.2 billion, marking a year-over-year increase of 189188.49%. This contributed to the annual value of $4.2 billion for FY2025, which is 189188.49% up from last year.
  • According to the latest figures from Q4 2025, Vertex Pharmaceuticals' Operating Income is $1.2 billion, which was up 1753.41% from $1.2 billion recorded in Q3 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Operating Income peaked at $1.2 billion during Q4 2025, and registered a low of -$3.5 billion during Q2 2024.
  • In the last 5 years, Vertex Pharmaceuticals' Operating Income had a median value of $1.0 billion in 2022 and averaged $743.1 million.
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Operating Income skyrocketed by 301899.74% in 2022, and later tumbled by 44242.99% in 2024.
  • Quarter analysis of 5 years shows Vertex Pharmaceuticals' Operating Income stood at $877.7 million in 2021, then increased by 17.75% to $1.0 billion in 2022, then dropped by 4.35% to $988.5 million in 2023, then grew by 3.79% to $1.0 billion in 2024, then increased by 17.53% to $1.2 billion in 2025.
  • Its last three reported values are $1.2 billion in Q4 2025, $1.2 billion for Q3 2025, and $1.2 billion during Q2 2025.